Search
for
Sort by
Research 181–210 of 1000+
- Pyruvate kinase M2 promotes hair regeneration by connecting metabolic and Wnt/β- catenin signaling
- [Significance of HLA-DR+ T cells and natural killer (NK) cells in the peripheral blood lymphocytes of alopecia areata (AA)].
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Efficacy of exosomes in acute kidney injury treatment and the associated mechanism (Review)
- Acute Kidney Injury following Ingestion of Topical Minoxidil
- 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Janus Kinase inhibitors in dermatology: a review
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- The role of janus kinases in the treatment of autoimmune skin diseases
- Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future
- 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
- Cell kinetics of the human hair follicle
- Simultaneous Typing of Erythrocyte Acid Phosphatase, Adenylate Kinase and Adenosine Deaminase in Human Hair Root Sheaths
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Perceived Efficacy and Risks of Janus Kinase Inhibitors in Pediatric and Young Adult Alopecia Areata: A Cross‐Sectional Survey
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial